Biognosys has announced the expansion of its contract research organisation (CRO) services to include quantitative biocrates, metabolomics and lipidomics.
These services will be offered both in Europe and from Biognosys’ US laboratory near Boston.
This strategic addition complements Biognosys’ mass spectrometry-based proteomics services and strengthens its global multiomics service portfolio.
The biocrates metabolomics/lipidomics services expansion follows on from Biognosys’ 2024 launch of targeted proteomics services as a Certified Service Provider of the ultra-high sensitivity NULISA technology.
This cements the role of Biognosys as a trusted service provider in high-precision multiomic biomarker discovery and quantification.
Biognosys will leverage the recently launched biocrates MxP Quant 1000 kit on Bruker’s EVOQ DART-TQ+ mass spectrometer (for research use only).
This validated workflow enables robust and standardised quantification of a broad panel of metabolites and lipids for Biognosys’ global customers for clinical and translational research.
The combination of the biocrates quality-controlled metabolomics and lipidomics kits with Bruker’s mass spectrometry platforms and the contract research services at Biognosys will give biopharma and clinical researchers access to scalable, quantitative multiomics designed for the highest data quality and reproducibility.
“We are excited to meet the growing customer demand for integrated proteomics and metabolomics services, offering a deeper, holistic view into biological systems,” said Jakob Vowinckel, PhD, Chief Officer Scientific Operations at Biognosys.
“We are pleased to see our MxP Quant 1000 kit expanding to a wider range of platforms, making quantitative metabolomics accessible to more laboratories and researchers,” said Sebastian Gottfried, PhD, biocrates Chief Marketing Officer.